Aster Capital Management’s NovoCure NVCR Stock Holding History

Aster Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-183	Closed	-$2.36K	–	1323
2025 Q3	$2.36K	Sell	183 -806	-81%	-$10.8K	﹤0.01%	863
2025 Q2	$17.6K	Buy	+989	New	+$17.2K	﹤0.01%	726
2025 Q1	–	Sell	-9	Closed	-$268	–	1550
2024 Q4	$268	Buy	+9	New	+$190	﹤0.01%	1049

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Aster Capital Management's NVCR Position: Q4 2025 in Review

Aster Capital Management sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 183 shares — an estimated $2.36K sold.

Aster Capital Management first reported a position in NVCR in Q4 2024 and held it in 3 quarters. The position peaked at $17.6K in Q2 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Aster Capital Management reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Aster Capital Management sold 183 NovoCure shares in Q4 2025, an estimated $2.36K.
Aster Capital Management first reported a position in NovoCure in Q4 2024 and held it in 3 quarters.
Aster Capital Management's NovoCure position peaked at $17.6K in Q2 2025.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Aster Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.